Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.

Stephan Kadauke,Regina M. Myers,Yimei Li,Richard Aplenc,Diane Baniewicz,David M. Barrett,Allison Barz Leahy,Colleen Callahan,Joseph G. Dolan,Julie C. Fitzgerald,Whitney L. Gladney,Simon F. Lacey,Hongyan Liu,Shannon L. Maude,Regina McGuire,Laura S. Motley,David T. Teachey,Gerald Wertheim,Lisa Wray,Amanda M. Dinofia,Stephan A. Grupp

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.

2021

PURPOSETo prospectively evaluate the effectiveness of risk-adapted preemptive tocilizumab (PT) administration in preventing severe cytokine release syndrome (CRS) after CTL019, a CD19 chimeric anti...

Keywords:

Cytokine release syndrome
Internal medicine
Tocilizumab
Medicine
Oncology
CD19
Clinical trial
B-cell acute lymphoblastic leukemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations